CLDX

Celldex Therapeutics Inc (CLDX) | Rumor.io

Celldex Therapeutics

CLDX

Attention (50-day avg)0%

Attention rank (50-day avg)#1,082

Bullish sentiment (50-day avg)22%

Price to earnings ratio-8.08

Market capitalization2.5B

Earnings per share-4.35

Dividend yield (TTM)—

Revenue (annual)1.5M

Net income (annual)-258.8M

Social

What share of all stock conversation is about CLDX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% 0	0% +0	0% 0

Sep 23

Morgan Stanley raised the price target on Celldex to $57 from $50, maintaining an Overweight rating, citing best-in-disease efficacy in EMBARQ-CSU and safety concerns.
Both Phase 3 CSU trials met primary endpoints, with the company planning to submit a BLA application in 2027, potentially leading to a market launch late 2027.
Analysts have raised their price targets on Celldex, with some predicting a buyout after BLA submission, while others note the stock's potential for profitability and a hit drug.

Generated by AI

Sentiment

Of the messages about CLDX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	90% +80.74	20.24% -79.76	54.25% -38.56
Bearish	—	10% -80.74	79.76% +79.76	45.75% +38.56

Bullish· Sep 25

Celldex Therapeutics, Inc. (CLDX) has seen a significant price increase of 11.35% since it was first alerted, indicating a strong market reaction to its data.
The company's recent data has been above expectations, with Wolfe Research and Wells Fargo both upgrading their outlook, citing positive results from its phase 2 trial and barzolvolimab data.
Shorts in CLDX have been heavily covered, with over 35% of them being closed out, suggesting a strong buying opportunity for investors.

Bearish· Sep 22

The company's late-stage trial data for a hives therapy showed a significant adverse event, leading to a black box warning, causing the stock to drop by 9%.
The stock experienced a sell-the-news event, where the initial positive result was followed by a sharp decline in price due to investors' concerns about the company's ability to commercialize the therapy.
The company's stock price plummeted by 40% due to uncertainty surrounding the trial data and potential dilution fears, with many investors believing the stock will recover over the next few months.

Generated by AI

Topics

Of the messages about CLDX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	0%	56.25%	7.88%	39.48%
Analysts	100%	40.63%	46.96%	31.93%
Technical Analysis	0%	3.13%	0.21%	3.98%
Macro	0%	0%	44.94%	24.38%
Controversies	0%	0%	0%	0.17%
Earnings	0%	0%	0%	0.06%

Earnings· May 9

Celldex Therapeutics, Inc. ($CLDX) reports earnings after the close, with an estimated +0.01 EPS and +0.53M Revs according to Estimize Consensus.
The estimated revenue is a key figure to watch, as it represents a significant increase compared to previous expectations.
The earnings report will provide insight into the company's financial performance and potential future growth prospects.

Analysts· Mar 8

HC Wainwright raised Celldex Therapeutics' price target to $25.00 with a buy rating.
Cowen and Company cut Celldex Therapeutics' price target to $12.00 with an outperform rating.
Jefferies and Wedbush downgraded Celldex Therapeutics to hold and neutral, respectively.

Announcements· Feb 25

Celldex Therapeutics has completed enrollment in its global Phase 3 studies (EMBARQ-CSU1 and EMBARQ-CSU2) of barzolvolimab in chronic spontaneous urticaria, with top-line data expected in Q4 2026.
The company completed enrollment six months ahead of schedule, driven by high unmet need, with 1,939 patients enrolled across 43 countries and 500+ sites.
Celldex reported Q4 2025 revenues of $121K, full-year $1.545M, with a Q4 net loss of $81.3M, and a cash position of $518.6M, with plans to submit a BLA for barzolvolimab in 2027.

Technical Analysis· May 7

$CLDX needs to hold above $0.73 to stay in the 20-day chart.
Failure to hold above $0.73 may trigger a major algo short attack.
$CLDX is expected to face earnings-related stress on Wednesday.

Generated by AI

Community

Of the messages about CLDX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	51.64%	49.63%	63.99%
Newcomers	0%	48.36%	50.37%	36.01%

Regulars· Sep 22

Celldex Therapeutics' barzolvolimab shows positive results in Phase 3 trials, meeting primary and all key secondary endpoints.
The company discloses two cases of Gr4 anaphylaxis in the Phase 3 trials, which may impact the stock's performance.
Analysts raise the price target on Celldex stock following the announcement of positive Phase 3 results, with some firms maintaining a Buy rating.

Newcomers· Sep 22

Celldex Therapeutics, Inc. announced positive results from Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 studies of barzolvolimab, meeting primary and all key secondary endpoints.
The stock price dropped from $53 to $22 and back to $30, causing some investors to suspect a "sell the news" event, where the price drops due to the anticipation of bad news.
Some users believe that the stock price will recover over the next months, as the clinical trial results are considered positive, but others are skeptical about the potential for adverse effects.

Generated by AI

News

Celldex Therapeutics Leads Guggenheim’s Biotechnology Rankings

6d agoInvesting.com

Can Celldex (CLDX) Overcome Its Heavy Burn Rate for Long-Term Success?

6d agoYahoo Finance

The Zacks Analyst Blog Highlights Kodiak Sciences, Celldex Therapeutics, Rapport Therapeutics and Vaxcyte

Four biotech companies face key fall readouts that could influence the development and commercial prospects of their pipelines.

6d agoYahoo Finance

Morgan Stanley raises Celldex Therapeutics price target on urticaria drug progress

7d agoInvesting.com

Celldex Therapeutics, Inc. (CLDX) Discusses Positive Phase 3 Results for Barzolvolimab in Chronic Spontaneous Urticaria - Slideshow (NASDAQ:CLDX) 2026-09-22

7d agoSeeking Alpha

Why is Celldex Therapeutics stock sliding today?

7d agoInvesting.com

Also Discussed

Investors talking about CLDX also mention

#	Name	Attention
1	Acadia Pharmaceuticals Inc.ACAD	0%+0
2	SGEN - Seagen Inc.	——
3	Incyte Corp.INCY	0%new
4	FOLD - Amicus Therapeutics, Inc.	——
5	BDSI - BioDelivery Sciences International, Inc.	——
6	iShares Biotechnology ETFIBB	0.01%0
7	Exelixis Inc.EXEL	0%-0.03
8	Halozyme Therapeutics Inc.HALO	0%0
9	MACK - Merrimack Pharmaceuticals, Inc.	——
10	HZNP - Horizon Therapeutics Public Limited Company	——

Celldex Therapeutics Inc

Healthcare
Biotechnology

Celldex Therapeutics Inc. is a biopharmaceutical company focused on developing antibody-based therapies for severe inflammatory, allergic, and autoimmune diseases. The company’s current programs center on monoclonal and bispecific antibodies designed to modulate mast cell biology and other immune pathways associated with chronic conditions that have limited treatment options. Its lead clinical assets include barzolvolimab, a KIT-targeting antibody being studied across several mast cell–driven disorders, and CDX-622, a bispecific candidate aimed at key inflammatory mechanisms. Celldex Therapeutics Inc. operates in the biotechnology sector and concentrates on advancing immunology-focused therapies through clinical development for patients with significant unmet medical needs. Headquartered in Hampton, New Jersey, the company is known for its specialized pipeline rather than a broad commercial product portfolio.

Website

Location

Perryville III Building

Hampton, NJ, 08827

United States

Social

What share of all stock conversation is about CLDX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% 0	0% +0	0% 0

Sep 23

Morgan Stanley raised the price target on Celldex to $57 from $50, maintaining an Overweight rating, citing best-in-disease efficacy in EMBARQ-CSU and safety concerns.
Both Phase 3 CSU trials met primary endpoints, with the company planning to submit a BLA application in 2027, potentially leading to a market launch late 2027.
Analysts have raised their price targets on Celldex, with some predicting a buyout after BLA submission, while others note the stock's potential for profitability and a hit drug.

Generated by AI

Sentiment

Of the messages about CLDX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	90% +80.74	20.24% -79.76	54.25% -38.56
Bearish	—	10% -80.74	79.76% +79.76	45.75% +38.56

Bullish· Sep 25

Celldex Therapeutics, Inc. (CLDX) has seen a significant price increase of 11.35% since it was first alerted, indicating a strong market reaction to its data.
The company's recent data has been above expectations, with Wolfe Research and Wells Fargo both upgrading their outlook, citing positive results from its phase 2 trial and barzolvolimab data.
Shorts in CLDX have been heavily covered, with over 35% of them being closed out, suggesting a strong buying opportunity for investors.

Bearish· Sep 22

The company's late-stage trial data for a hives therapy showed a significant adverse event, leading to a black box warning, causing the stock to drop by 9%.
The stock experienced a sell-the-news event, where the initial positive result was followed by a sharp decline in price due to investors' concerns about the company's ability to commercialize the therapy.
The company's stock price plummeted by 40% due to uncertainty surrounding the trial data and potential dilution fears, with many investors believing the stock will recover over the next few months.

Generated by AI

Topics

Of the messages about CLDX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	0%	56.25%	7.88%	39.48%
Analysts	100%	40.63%	46.96%	31.93%
Technical Analysis	0%	3.13%	0.21%	3.98%
Macro	0%	0%	44.94%	24.38%
Controversies	0%	0%	0%	0.17%
Earnings	0%	0%	0%	0.06%

Earnings· May 9

Celldex Therapeutics, Inc. ($CLDX) reports earnings after the close, with an estimated +0.01 EPS and +0.53M Revs according to Estimize Consensus.
The estimated revenue is a key figure to watch, as it represents a significant increase compared to previous expectations.
The earnings report will provide insight into the company's financial performance and potential future growth prospects.

Analysts· Mar 8

HC Wainwright raised Celldex Therapeutics' price target to $25.00 with a buy rating.
Cowen and Company cut Celldex Therapeutics' price target to $12.00 with an outperform rating.
Jefferies and Wedbush downgraded Celldex Therapeutics to hold and neutral, respectively.

Announcements· Feb 25

Celldex Therapeutics has completed enrollment in its global Phase 3 studies (EMBARQ-CSU1 and EMBARQ-CSU2) of barzolvolimab in chronic spontaneous urticaria, with top-line data expected in Q4 2026.
The company completed enrollment six months ahead of schedule, driven by high unmet need, with 1,939 patients enrolled across 43 countries and 500+ sites.
Celldex reported Q4 2025 revenues of $121K, full-year $1.545M, with a Q4 net loss of $81.3M, and a cash position of $518.6M, with plans to submit a BLA for barzolvolimab in 2027.

Technical Analysis· May 7

$CLDX needs to hold above $0.73 to stay in the 20-day chart.
Failure to hold above $0.73 may trigger a major algo short attack.
$CLDX is expected to face earnings-related stress on Wednesday.

Generated by AI

Community

Of the messages about CLDX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	51.64%	49.63%	63.99%
Newcomers	0%	48.36%	50.37%	36.01%

Regulars· Sep 22

Celldex Therapeutics' barzolvolimab shows positive results in Phase 3 trials, meeting primary and all key secondary endpoints.
The company discloses two cases of Gr4 anaphylaxis in the Phase 3 trials, which may impact the stock's performance.
Analysts raise the price target on Celldex stock following the announcement of positive Phase 3 results, with some firms maintaining a Buy rating.

Newcomers· Sep 22

Celldex Therapeutics, Inc. announced positive results from Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 studies of barzolvolimab, meeting primary and all key secondary endpoints.
The stock price dropped from $53 to $22 and back to $30, causing some investors to suspect a "sell the news" event, where the price drops due to the anticipation of bad news.
Some users believe that the stock price will recover over the next months, as the clinical trial results are considered positive, but others are skeptical about the potential for adverse effects.

Generated by AI

Celldex Therapeutics

Social

Sep 23

Bullish· Sep 25

Bearish· Sep 22

Earnings· May 9

Analysts· Mar 8

Announcements· Feb 25

Technical Analysis· May 7

Regulars· Sep 22

Newcomers· Sep 22

Celldex Therapeutics Leads Guggenheim’s Biotechnology Rankings

Can Celldex (CLDX) Overcome Its Heavy Burn Rate for Long-Term Success?

The Zacks Analyst Blog Highlights Kodiak Sciences, Celldex Therapeutics, Rapport Therapeutics and Vaxcyte

Morgan Stanley raises Celldex Therapeutics price target on urticaria drug progress

Celldex Therapeutics, Inc. (CLDX) Discusses Positive Phase 3 Results for Barzolvolimab in Chronic Spontaneous Urticaria - Slideshow (NASDAQ:CLDX) 2026-09-22

Why is Celldex Therapeutics stock sliding today?

Also Discussed

Celldex Therapeutics Inc

Company Information

Location

Celldex Therapeutics Leads Guggenheim’s Biotechnology Rankings

Can Celldex (CLDX) Overcome Its Heavy Burn Rate for Long-Term Success?

The Zacks Analyst Blog Highlights Kodiak Sciences, Celldex Therapeutics, Rapport Therapeutics and Vaxcyte

Morgan Stanley raises Celldex Therapeutics price target on urticaria drug progress

Celldex Therapeutics, Inc. (CLDX) Discusses Positive Phase 3 Results for Barzolvolimab in Chronic Spontaneous Urticaria - Slideshow (NASDAQ:CLDX) 2026-09-22

Why is Celldex Therapeutics stock sliding today?

Also Discussed

Social

Sep 23

Bullish· Sep 25

Bearish· Sep 22

Earnings· May 9

Analysts· Mar 8

Announcements· Feb 25

Technical Analysis· May 7

Regulars· Sep 22

Newcomers· Sep 22